The abnormal status of uncarboxylated matrix Gla protein species represents an additional mortality risk in heart failure patients with vascular disease

Otto, Jr. Mayer*, Jitka Seidlerova, Jiri Vanek, Petra Karnosova, Jan Bruthans, Jan Filipovsky, Peter Wohlfahrt, Renata Cifkova, Jindra Windrichova, Maria Knapen, Nadja E. A. Drummen, Cees Vermeer

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Background: Matrix Gla protein (MGP) is a natural inhibitor of tissue calcification. In a previous study, we observed the positive association between abnormal concentrations of uncarboxylatedMGP species and increased mortality risk in stable vascular patients. We explore whether co-incidence of abnormal status of uncarboxylated MPG and heart failure (HF) affects the mortality risk. Methods: We examined 799 patients (mean age 65.1 years) with stable vascular disease and followed them in a prospective study. Both, desphospho-uncarboxylated and total uncarboxylated MGP (dp-ucMGP or t-ucMGP) were quantified by pre-commercial ELISA assays. Results: Elevated (>100 ng/L) circulating brain natriuretic peptide (BNP) and abnormal status of plasma uncarboxylated MGP species (i.e.: dp-ucMGP >= 977 pmol/L or t-ucMGP
Original languageEnglish
Pages (from-to)916-922
JournalInternational Journal of Cardiology
Volume203
DOIs
Publication statusPublished - 15 Jan 2016

Keywords

  • Matrix gamma-carboxyl glutamate protein (MGP)
  • Heart failure
  • dp-ucMGP
  • t-ucMGP
  • Mortality
  • Atherovascular disease

Fingerprint

Dive into the research topics of 'The abnormal status of uncarboxylated matrix Gla protein species represents an additional mortality risk in heart failure patients with vascular disease'. Together they form a unique fingerprint.

Cite this